<DOC>
	<DOC>NCT02078427</DOC>
	<brief_summary>The purpose of the study is to document the natural history of hemophilia. A disease and long-term outcomes in terms of effectiveness, safety and quality of life (QoL) in participants receiving ADVATE in routine clinical practice. Participants may use any treatment regimen, including on-demand and prophylaxis using standardized regimens or individual pharmacokinetic (PK)-guided dosing regimens, or immune tolerance induction (ITI) therapy, as determined by the treating physician.</brief_summary>
	<brief_title>ADVATE Hemophilia A Outcome Database (AHEAD)</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Participant has hemophilia A (Factor VIII (FVIII) â‰¤5%) Participant is prescribed ADVATE by the treating physician Participant or participant's legally authorized representative provides informed consent Participant has known hypersensitivity to the active substance or any of the excipients Participant has known allergic reaction to mouse or hamster proteins Participant has participated in another clinical study involving an investigational product (IP) or device within 30 days prior to study enrollment or is scheduled to participate in another clinical study involving another FVIII concentrate or device during the course of this study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>